GlaxoSmithKline faces fresh bribery allegations in Syria
Anonymous source claims Syrian staff paid medical officials to use GSK medicines
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Britain’s biggest drugmaker GlaxoSmithKline is facing fresh bribery allegations after an anonymous tip-off claimed the firm was paying doctors and officials to boost sales of its medicines.
GSK — whose executives are under investigation for bribery in China — is also facing corruption allegations in its non-prescription business in Syria.
But an anonymous email sent to GSK’s chief executive Sir Andrew Witty and head of the pharmaceutical giant’s audit committee, Judy Lewent, reads: “GSK has been engaging in multiple corrupt and illegal practices in conducting its pharmaceutical business in Syria.”
The email, which was seen by Reuters, claims Syrian staff paid medical officials to push medicines including ones to treat cancer and to prevent blood clots.
Brentford-based Glaxo said: “All the claims in this email will be thoroughly investigated as part of our ongoing investigation into operations in Syria.” It has suspended business with its Syrian distributors.
The Serious Fraud Office has launched a formal criminal investigation into GSK’s overseas activities, after it faced bribery claims in Iraq, Jordan, Lebanon and Poland as well as China. The US Department of Justice is also investigating GSK for possible breaches of the Foreign Corrupt Practices Act.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments